Revolutionizing drug discovery: The impact of artificial intelligence on advancements in pharmacology and the pharmaceutical industry

Abstract

To create novel treatments and treat complex diseases, the pharmaceutical sector is essential. Drug discovery, however, is a time-consuming, pricey, and dangerous endeavor. Artificial intelligence (AI) has become a potent instrument that has transformed several industries, including healthcare, in recent years. This summary gives a general overview of how AI is expediting the creation of novel medicines, revolutionizing the pharmaceutical sector, and enabling drug discovery. The pharmaceutical sector is experiencing a drug discovery revolution because of AI. The drug discovery process is changing at different phases because of AI approaches like machine learning and deep learning. This abstract demonstrates how AI facilitates drug development through target identification, lead compound optimization, drug design, drug repurposing, and clinical trial enhancement. AI integration has the potential to hasten the creation of novel treatments, save costs, and improve patient outcomes. To fully realize the potential of AI in pharmaceutical research and development, issues relating to data accessibility, algorithm interpretability, and laws must be resolved.

Keywords

Artificial intelligence / AI pharmacology / AI in drug discovery / Medical diagnosis / Clinical trials

References

[1] Chen W, Liu X, Zhang S, Chen S. Artificial intelligence for drug discovery: resources, methods, and applications. Mol Ther Nucleic Acids. 2023;31(March):691–702.

[2] Xu Y, Liu X, Cao X, et al. Artificial intelligence: a powerful paradigm for scientific research. Innovation. 2021;2(4).

[3] Aldoseri A, Al-Khalifa KN, Hamouda AM. Re-thinking data strategy and integration for artificial intelligence: concepts, opportunities, and challenges. Appl Sci. 2023;13(12).

[4] Taye MM. Understanding of machine learning with deep learning: architectures, workflow, applications and future directions. Computers. 2023;12(5).

[5] Tarle S, Kakad A, Shaikh MRN. Review article overview : embracing tools of artificial intelligence in. Pharmaceuticals. 2023;4(6):5749–5755.

[6] Krenn M, Pollice R, Guo SY, et al. On scientific understanding with artificial intelligence. Nat Rev Phys. 2022;4(12):761–769.

[7] Denecke K, Baudoin CR. A review of artificial intelligence and robotics in transformed health ecosystems. Front Med. 2022;9(July):1–13.

[8] Deiana AMC, Tran N, Agar J, et al. Applications and techniques for fast machine learning in science. Front Big Data. 2022;5(April):1–56. https://doi.org/10.3389/fdata.2022.787421.

[9] Sarkar C, Das B, Rawat VS, et al. Artificial intelligence and machine learning technology driven modern drug discovery and development. Int J Mol Sci. 2023;24(3).

[10] Fei N, Lu Z, Gao Y, et al. Towards artificial general intelligence via a multimodal foundation model. Nat Commun. 2022;13(1):1–13. https://doi.org/10.1038/S41467-022-30761-2.

[11] Reiners D, Davahli MR, Karwowski W, Cruz-Neira C. The combination of artificial intelligence and extended reality: a systematic review. Front Virtual Real. 2021;2(September):1–13.

[12] Bhattamisra SK, Banerjee P, Gupta P, Mayuren J, Patra S, Candasamy M. Artificial intelligence in pharmaceutical and healthcare research. Big Data Cogn Comput. 2023;7(1):10.

[13] Fleming N. AI in drug discovery. Nature. 2018;(March):5–7.

[14] Patil P, Nrip N, Hajare A, et al. Artificial intelligence and tools in pharmaceuticals: an overview. 2023;16:2075–2082.

[15] Segler M, Preuss M, Waller MP. Towards “Alphachem”: Chemical Synthesis Planning with Tree Search and Deep Neural Network Policies. 5th Int Conf Learn Represent ICLR 2017 -Work Track Proc;2017:1–4, 2014.

[16] Gaidhani KA, Harwalkar M, Nirgude PS. World journal of pharmaceutical ReseaRch SEED EXTRACTS. World J Pharmaceut Res. 2014;3(3):5041–5048. https://doi.org/10.20959/wjpr201911-15964.

[17] Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A. Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data. Mol Pharm. 2016;13(7):2524–2530.

[18] Wu J, Kong L, Yi M, et al. Prediction and screening model for products based on fusion regression and XGBoost classification. Comput Intell Neurosci. 2022:2022.

[19] Dara S, Dhamercherla S, Jadav SS, Babu CM, Ahsan MJ. Machine Learning in Drug Discovery: A Review. vol. 55. Springer Netherlands;2022. https://doi.org/10.1007/S10462-021-10058-4.

[20] Oyelade J, Isewon I, Oladipupo F, et al. Clustering algorithms: their application to gene expression data. Bioinf Biol Insights. 2016;10:237–253.

[21] Borisa Pooja, Debjani Singh KSR. Impact of artificial intelligence on pharma industry. Manipal J Pharm Sci |. 2020;6(1):54–59.

[22] Ahmed SF, Alam MS Bin, Hassan M, et al. Deep Learning Modelling Techniques: Current Progress, Applications, Advantages, and Challenges. vol. 56. Springer Netherlands;2023.

[23] Cè M, Irmici G, Foschini C, et al. Artificial intelligence in brain tumor imaging: a step toward personalized medicine. Curr Oncol. 2023;30(3):2673–2701.

[24] Sheikh H, Prins C, Schrijvers E. Mission AI: The New System Technology. 2023.

[25] Patel J, Patel D, Meshram D. Artificial intelligence in pharma industry-A rising concept. J Adv Pharmacogn. 2021;1(2):54–64.

[26] Bohr A, Memarzadeh K. The Rise of Artificial Intelligence in Healthcare Applications.2020.

[27] Johnson KB, Wei WQ, Weeraratne D, et al. Precision medicine, AI, and the future of personalized health care. Clin Transl Sci. 2021;14(1):86–93.

[28] Al-Antari MA. Artificial intelligence for medical diagnostics—existing and future AI technology. Diagnostics. 2023;13(4):1–3.

[29] Çelik IN, Arslan FK, Tun R, Yildiz I. Artificial intelligence on drug discovery and development. Ank Univ Eczacilik Fak Derg. 2022;46(2):400–427. https://doi.org/10.33483/jfpau.878041q.

[30] Alowais SA, Alghamdi SS, Alsuhebany N, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med Educ. 2023;23(1):1–15.

[31] Al Kuwaiti A, Nazer K, Al-Reedy A, et al. A review of the role of artificial intelligence in healthcare. J Personalized Med. 2023;13(6):1–22.

[32] Maia E, Vieira P, Praça I. Empowering preventive care with GECA chatbot. Health. 2023;11(18).

[33] Duijnhoven RG, Straus SMJM, Raine JM, de Boer A, Hoes AW, de Bruin ML. Number of patients studied prior to approval of new medicines: a database analysis. PLoS Med. 2013;10(3):1–8.

[34] Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11(July):156–164.

[35] Ahuja AS. The impact of artificial intelligence in medicine on the future role of the physician. PeerJ. 2019;2019(10).

[36] Verma H, Mlynar J, Schaer R, et al. Re-Thinking the role of AI with physicians in oncology: revealing perspec-tives from clinical and research workflows. 2023;19.

[37] Cheng F, Liu C, Jiang J, et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol. 2012;8(5).

[38] Wang W, Yang S, Zhang X, Li J. Drug repositioning by integrating target information through a heterogeneous network model. Bioinformatics. 2014;30(20):2923–2930.

[39] Jarada TN, Rokne JG, Alhajj R. A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions. J Cheminf. 2020;12(1):1–23.

[40] Bi WL, Hosny A, Schabath MB, et al. Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin. 2019;69(2):127–157.

[41] Prasad K, Kumar V. Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2. Curr Res Pharmacol Drug Discov. 2021;2(May):100042.

[42] Olayan RS, Ashoor H, Bajic VBDDR. Efficient computational method to predict drug-Target interactions using graph mining and machine learning approaches. Bioinformatics. 2018;34(7):1164–1173.

[43] Wang X, Li Q, Liu Y, Du Z, Jin R. Drug repositioning of COVID-19 based on mixed graph network and ion channel. Math Biosci Eng. 2022;19(4):3269–3284.

[44] Meng Y, Wang Y, Xu J, et al. Drug repositioning based on weighted local information augmented graph neural network. Briefings Bioinf. 2024;25(1):1–12.

[45] Xuan P, Song Y, Zhang T, Jia L. Prediction of potential drug-disease associations through deep integration of diversity and projections of various drug features. Int J Mol Sci. 2019;20(17):1–17.

[46] Delcher C, Moga D, Li Y, Muñoz M, Sohn M, Bae J. Pharmacoepidemiology and pharmacovigilance. Remingt Sci Pract Pharm. 2020:899–913. Published online.

[47] Gelfand JM, Noe MH. Pharmacovigilance. 4th ed. Elsevier;2020. https://doi.org/10.1016/B978-0-323-61211-1.00007-3.

[48] Hamid AAA, Rahim R, Teo SP. Pharmacovigilance and its importance for primary health care professionals. Korean J Fam Med. 2022;43(5):290–295.

[49] Jeetu G, Anusha G. Pharmacovigilance: a worldwide master key for drug safety monitoring. J Young Pharm. 2010;2(3):315–320.

[50] Harrison R, Walton M, Manias E, et al. The missing evidence: a systematic review of patients’ experiences of adverse events in health care. Int J Qual Health Care. 2015;27(6):424–442.

[51] Ouoba K, Lehmann H, Zongo A, Pabst JY, Semdé R. Current status and challenges of pharmacovigilance of traditional medicines in French-speaking West African (UEMOA) countries. Pharmaceut Med. 2023;37(4):305–318.

[52] Li C, Chen Y, Shang Y. A review of industrial big data for decision making in intelligent manufacturing. Eng Sci Technol an Int J. 2022;29:101021.

[53] Kumar Sethi MPU. Pharmacovigilance: challenges in India. J Pharmacovigil. 2016;4(1):1000194.

[54] Cowie MR, Blomster JI, Curtis LH, et al. Electronic health records to facilitate clinical research. Clin Res Cardiol. 2017;106(1):1–9.

[55] Trifirò G, Crisafulli S. A new era of pharmacovigilance: future challenges and opportunities. Front Drug Saf Regul. 2022;2(February):2020–2023.

[56] Sloane R, Osanlou O, Lewis D, Bollegala D, Maskell S, Pirmohamed M. Social media and pharmacovigilance: a review of the opportunities and challenges. Br J Clin Pharmacol. 2015;80(4):910–920.

[57] Ross MK, Wei W, Ohno-Machado L. “Big data” and the electronic health record. Yearb Med Inform. 2014;9:97–104.

[58] Ball R, Dal Pan G. “Artificial intelligence” for pharmacovigilance: ready for prime time? Drug Saf. 2022;45(5):429–438.

[59] Mohammed KI, Zaidan AA, Zaidan BB, et al. Real-time remote-health monitoring systems: a review on patients prioritisation for multiple-chronic diseases, taxonomy analysis, concerns and solution procedure. J Med Syst. 2019;43(7).

[60] Wani P, Shelke A, Marwadi M, Somase V, Borade P, Pansare K. Role of artificial intelligence in pharmacovigilance: a concise review. 2022;13(7):6149–6156. https://doi.org/10.47750/pnr.2022.13.S07.747.

[61] Khalid S, Khan MA, Mazliham MS, et al. Predicting risk through artificial intelligence based on machine learning algorithms: a case of Pakistani nonfinancial firms. Complexity. 2022:2022. November 2019.

[62] Gonzalez-Hernandez G, Krallinger M, Muñoz M, Rodriguez-Esteban R, Uzuner Ö, Hirschman L. Challenges and opportunities for mining adverse drug reactions: perspectives from pharma, regulatory agencies, healthcare providers and consumers. Database. 2022;2022(00):1–10.

[63] Bate A, Stegmann JU. Artificial intelligence and pharmacovigilance: what is happening, what could happen and what should happen? Heal Policy Technol. 2023;12(2):100743.

[64] Belhekar MN, Taur SR, Munshi RP. A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions. Indian J Pharmacol. 2014;46(1):117–120.

[65] Bouaziz M. The Future of Pharmacovigilance with the Use of Artificial Intelligence Sounds Good..

[66] Sahu A, Mishra J, Kushwaha N. Artificial intelligence (AI) in drugs and pharmaceuticals. Comb Chem High Throughput Screen. 2022;25(11):1818–1837.

[67] Ece A. Computer-aided drug design. BMC Chem. 2023;17(1):1–3.

[68] Kim HY, Cho GJ, Kwon HS. Applications of artificial intelligence in obstetrics. Ultrasonography. 2023;42(1):2–9.

[69] Sarkis M, Bernardi A, Shah N, Papathanasiou MM. Emerging challenges and opportunities in pharmaceutical manufacturing and distribution. Processes. 2021;9(3):1–16.

[70] Khalid GM, Usman AG. Application of data-intelligence algorithms for modeling the compaction performance of new pharmaceutical excipients. Futur J Pharm Sci. 2021;7(1).

[71] Lohit N, Singh AK, Kumar A, et al. Description and in silico ADME studies of USFDA approved drugs or drugs under clinical trial which violate the Lipinski’s rule of 5. Lett Drug Des Discov. 2023;20:3–5.

[72] Minbaleev AV. The concept of “artificial intelligence” in law. Bull Udmurt Univ Ser Econ Law. 2022;32(6):1094–1099.

[73] Rantanen J, Khinast J. The future of pharmaceutical manufacturing sciences. J Pharmaceut Sci. 2015;104(11):3612–3638.

[74] Overgaard SM, Graham MG, Brereton T, et al. Implementing quality management systems to close the AI translation gap and facilitate safe, ethical, and effective health AI solutions. npj Digit Med. 2023;6(1).

[75] Hole G, Hole AS, McFalone-Shaw I. Digitalization in pharmaceutical industry: what to focus on under the digital implementation process? Int J Pharm X. 2021;3:100095.

[76] Tirkolaee EB, Sadeghi S, Mooseloo FM, Vandchali HR, Aeini S. Application of machine learning in supply chain management: a comprehensive overview of the main areas. Math Probl Eng. 2021;2021(Ml).

[77] Parvathaneni M, Awol AK, Kumari M, Lan K, Lingam M. Application of artificial intelligence and machine learning in drug discovery and development. J Drug Deliv Therapeut. 2023;13(1):151–158.

[78] Iqbal S, Qureshi AN, Li J, Mahmood T. On the Analyses of Medical Images Using Traditional Machine Learning Techniques and Convolutional Neural Networks. vol. 30. Springer Netherlands;2023.

[79] Tang X. The role of artificial intelligence in medical imaging research. BJR|Open. 2020;2(1):20190031.

[80] Fogarasi M, Coburn JC, Ripley B. Algorithms used in medical image segmentation for 3D printing and how to understand and quantify their performance. 3D Print Med. 2022:1–15. Published online.

[81] Karalis VD. The integration of artificial intelligence into clinical practice. Published online. 2024:14–44.

[82] Gomes RFT, Schmith J, Figueiredo RM de, et al. Use of artificial intelligence in the classification of elementary oral lesions from clinical images. Int J Environ Res Publ Health. 2023;20(5).

[83] Puttagunta M, Ravi S. Medical image analysis based on deep learning approach. Multimed Tool Appl. 2021;80(16):24365–24398. https://doi.org/10.1007/S11042-021-10707-4.

[84] Ghaffar N, Erkan N, Ahad K. Evaluation of artificial intelligence techniques in disease diagnosis and prediction. Discov Artif Intell.2023. https://doi.org/10.1007/S44163-023-00049-5. Published online.

[85] Kumar Y, Koul A, Singla R, Ijaz MF. Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agenda. J Ambient Intell Hum Comput. 2023;14(7):8459–8486.

[86] Pierre K, Haneberg AG, Kwak S, et al. Applications of artificial intelligence in the radiology roundtrip: process streamlining, workflow optimization, and beyond. Semin Roentgenol. 2023;58(2):158–169.

[87] Jellinger KA. The neuropathological diagnosis of Alzheimer disease. J Neural Transm Suppl. 1998;5(53):97–118.

[88] Antwi WK, Akudjedu TN, Botwe BO. Artificial intelligence in medical imaging practice in Africa: a qualitative content analysis study of radiographers’ perspectives. Insights Imaging. 2021;12(1).

[89] Mintz Y, Brodie R. Introduction to artificial intelligence in medicine. Minim Invasive Ther Allied Technol. 2019;28(2):73–81.

[90] Yuan C, Ryan PB, Ta C, et al. Criteria2Query: a natural language interface to clinical databases for cohort definition. J Am Med Inf Assoc. 2019;26(4):294–305.

[91] Wong A, Plasek JM, Montecalvo SP, Zhou L. Natural language processing and its implications for the future of medication safety: a narrative review of recent advances and challenges. Pharmacother J Hum Pharmacol Drug Ther. 2018;38(8):822–841.

[92] Del Rio-Bermudez C, Medrano IH, Yebes L, Poveda JL. Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy. J Pharm Policy Pract. 2020;13(1):4–9.

[93] Huang WT, Hung HH, Kao YW, et al. Application of neural network and cluster analyses to differentiate TCM patterns in patients with breast cancer. Front Pharmacol. 2020;11:670.

[94] Kumar M, Nguyen TPN, Kaur J, et al. Opportunities and challenges in application of artificial intelligence in pharmacology. Pharmacol Rep. 2023;75(1):3–18.

[95] Javaid M, Haleem A, Singh RP, Suman R. Towards insighting cybersecurity for healthcare domains: a comprehensive review of recent practices and trends. Cyber Secur Appl. 2023;1(December).

[96] Yeboah-Ofori A, Islam S. Cyber security threat modeling for supply chain organizational environments. Future Internet. 2019;11(3).

[97] Sarker IH. Machine learning for intelligent data analysis and automation in cybersecurity: current and future prospects. Ann Data Sci. 2023;10(6):1473–1498.

[98] Sarker IH. Machine learning: algorithms, real-world applications and research directions. SN Comput Sci. 2021;2(3):1–21.

[99] Yaacoub JPA, Noura HN, Salman O, Chehab A. Robotics cyber security: vulnerabilities, attacks, countermeasures, and recommendations. Int J Inf Secur. 2022;21(1):115–158.

[100] Xiang D, Cai W. Privacy protection and secondary use of health data: strategies and methods. BioMed Res Int. 2021:2021.

[101] Forcier MB, Gallois H, Mullan S, Joly Y. Integrating artificial intelligence into health care through data access: can the GDPR act as a beacon for policymakers? J Law Biosci. 2019;6(1):317–335.

[102] Jarab AS, Abu Heshmeh SR, Al Meslamani AZ. Artificial intelligence (AI) in pharmacy: an overview of innovations. J Med Econ. 2023;26(1):1261–1265.

[103] Tagde P, Tagde S, Bhattacharya T, et al. Blockchain and artificial intelligence technology in e-Health. Environ Sci Pollut Res. 2021;28(38):52810–52831.

[104] Kaur R, Gabrijelčič D, Klobučar T. Artificial intelligence for cybersecurity: literature review and future research directions. Inf Fusion. 2023;97(January).

[105] Atlam HF, Walters RJ, Wills GB, Daniel J. Fuzzy logic with expert judgment to implement an adaptive risk-based access control model for IoT. Mobile Network Appl. 2021;26(6):2545–2557.

[106] Rukhiran M, Wong-In S, Netinant P. User acceptance factors related to biometric recognition technologies of examination attendance in higher education: TAM model. Sustain Times. 2023;15(4).

[107] Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci. 2019;40(8):577–591.

[108] van der Lee M, Swen JJ. Artificial intelligence in pharmacology research and practice. Clin Transl Sci. 2023;16(1):31–36.

[109] Yadav JP, Kumar A, Maria S, Prateek G, Amita P, Vikas V. Insights into the Mechanisms of Diabetic Wounds: Pathophysiology, Molecular Targets, and Treatment Strategies through Conventional and Alternative Therapies. Springer International Publishing;2024.

[110] Jabeen A, Ranganathan S. Applications of machine learning in GPCR bioactive ligand discovery. Curr Opin Struct Biol. 2019;55:66–76.

[111] Durairaj M, Ranjani V. Data mining applications in healthcare sector: a study. Int J Sci Technol Res. 2013;2(10):29–35.

[112] Palanisamy V, Thirunavukarasu R. Implications of big data analytics in developing healthcare frameworks–A review. J King Saud Univ Inf Sci. 2019;31(4):415–425.

[113] Seyhan AA, Carini C. Are innovation and new technologies in precision medicine paving a new era in patients centric care? J Transl Med. 2019;17:1–28.

[114] Bertucci F, Lcs AG, Monneur A, et al. E-health and “Cancer outside the hospital walls”, Big Data and artificial intelligence. Bull Cancer. 2019;107(1):102–112.

[115] Tobore I, Li J, Yuhang L, et al. Deep learning intervention for health care challenges: some biomedical domain considerations. JMIR mHealth uHealth. 2019;7(8):e11966.

[116] Pal J, Kumar D, Verma A, Pathak P. Revolutionizing diabetic wound healing: targeted therapeutic strategies based on growth factors. Obes Med. 2024;47(January):100535.

[117] Yadav JP. Based on clinical research matrix metalloprotease (MMP) inhibitors to promote diabetic wound healing. Horm Metab Res. 2023;55(11):752–757.

[118] Kolla L, Gruber FK, Khalid O, Hill C, Parikh RB. The case for AI-driven cancer clinical trials-The efficacy arm in silico. Biochim Biophys Acta, Rev Cancer. 2021;1876(1):188572.

[119] Yousefirizi F, Decazes P, Amyar A, Ruan S, Saboury B, Rahmim A. AI-based detection, classification and prediction/prognosis in medical imaging: towards radiophenomics. Pet Clin. 2022;17(1):183–212.

[120] van Laar SA, Gombert-Handoko KB, Guchelaar H, Zwaveling J. An electronic health record text mining tool to collect real-world drug treatment outcomes: a validation study in patients with metastatic renal cell carcinoma. Clin Pharmacol Ther. 2020;108(3):644–652.

[121] Venkatapurapu SP, Iwakiri R, Udagawa E, et al. A computational platform integrating a mechanistic model of Crohn’s disease for predicting temporal progression of mucosal damage and healing. Adv Ther. 2022;39(7):3225–3247.

[122] Sweilam NH, Tharwat AA, Moniem NKA. Support vector machine for diagnosis cancer disease: a comparative study. Egypt Informatics J. 2010;11(2):81–92.

[123] Orru G, Pettersson-Yeo W, Marquand AF, Sartori G, Mechelli A. Using support vector machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review. Neurosci Biobehav Rev. 2012;36(4):1140–1152.

[124] Dheeba J, Singh NA, Selvi ST. Computer-aided detection of breast cancer on mammograms: a swarm intelligence optimized wavelet neural network approach. J Biomed Inf. 2014;49:45–52.

[125] Khedher L, Ramírez J, Górriz JM, Brahim A, Segovia F. Early diagnosis of Alzheimer’s disease based on partial least squares, principal component analysis and support vector machine using segmented MRI images. Neurocomputing. 2015;151(P1):139–150.

[126] Gulshan V, Peng L, Coram M, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA. 2016;316(22):2402–2410.

[127] Griffis JC, Allendorfer JB, Szaflarski JP. Voxel-based Gaussian naïve Bayes classification of ischemic stroke lesions in individual T1-weighted MRI scans. J Neurosci Methods. 2016;257:97–108.

[128] Kamnitsas K, Ledig C, Newcombe VFJ, et al. Efficient multi-scale 3D CNN with fully connected CRF for accurate brain lesion segmentation. Med Image Anal. 2017;36:61–78.

[129] Long E, Lin H, Liu Z, et al. An artificial intelligence platform for the multihospital collaborative management of congenital cataracts. Nat Biomed Eng. 2017;1(2):24.

[130] Smith GF. Artificial intelligence in drug safety and metabolism. Artif Intell Drug Des. 2022:483–501. Published online.

[131] van Gelder T, Vinks AA. Machine learning as a novel method to support therapeutic drug management and precision dosing. Clin Pharmacol Ther. 2021;110(2):273–276.

[132] Labriffe M, Woillard J, Debord J, Marquet P. Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles. CPT Pharmacometrics Syst Pharmacol. 2022;11(8):1018–1028.

[133] McInnes G, Dalton R, Sangkuhl K, et al. Transfer learning enables prediction of CYP2D6 haplotype function. PLoS Comput Biol. 2020;16(11):e1008399.

[134] Kim H, Kim E, Lee I, Bae B, Park M, Nam H. Artificial intelligence in drug discovery: a comprehensive review of data-driven and machine learning approaches. Biotechnol Bioproc Eng. 2020;25:895–930.

[135] Rifaioglu AS, Atas H, Martin MJ, Cetin-Atalay R, Atalay V, Doğan T. Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and databases. Briefings Bioinf. 2019;20(5):1878–1912.

[136] Morris GM, Lim-Wilby M. Molecular docking. Mol Model proteins. 2008:365–382. Published online.

[137] Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461.

[138] Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739–1749.

[139] Ewing TJA, Makino S, Skillman AG, Kuntz ID. Dock 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des. 2001;15:411–428.

[140] Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci. 2019;20(18):4331.

[141] Ballester PJ, Mitchell JBO. A machine learning approach to predicting protein–ligand binding affinity with applications to molecular docking. Bioinformatics. 2010;26(9):1169–1175.

[142] Fan N, Bauer CA, Stork C, de Bruyn Kops C, Kirchmair J. ALADDIN: docking approach augmented by machine learning for protein structure selection yields superior virtual screening performance. Mol Inform. 2020;39(4):1900103.

[143] Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers. 2021;25:1315–1360.

[144] Jiménez-Luna J, Cuzzolin A, Bolcato G, Sturlese M, Moro S. A deep-learning approach toward rational molecular docking protocol selection. Molecules. 2020;25(11):2487.

[145] Yang X, Wang Y, Byrne R, Schneider G, Yang S. Concepts of artificial intelligence for computer-assisted drug discovery. Chem Rev. 2019;119(18):10520–10594.

[146] Dai W, Guo D. A ligand-based virtual screening method using direct quantification of generalization ability. Molecules. 2019;24(13):2414.

[147] Lima AN, Philot EA, Trossini GHG, Scott LPB, Maltarollo VG, Honorio KM. Use of machine learning approaches for novel drug discovery. Expet Opin Drug Discov. 2016;11(3):225–239.

[148] Abdolmaleki A, Ghasemi JB. Inhibition activity prediction for a dataset of candidates’ drug by combining fuzzy logic with MLR/ANN QSAR models. Chem Biol Drug Des. 2019;93(6):1139–1157.

[149] Žuvela P, David J, Wong MW. Interpretation of ANN-based QSAR models for prediction of antioxidant activity of flavonoids. J Comput Chem. 2018;39(16):953–963.

[150] Paolini GV, Shapland RHB, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat Biotechnol. 2006;24(7):805–815.

[151] Gottlieb A, Stein GY, Ruppin E, Sharan R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol. 2011;7(1):496.

[152] Xia Z, Wu LY, Zhou X, Wong STC. Semi-supervised drug-protein interaction prediction from heterogeneous biological spaces. BMC Syst Biol. 2010;4:1–16. BioMed Central.

[153] Luo Y, Zhao X, Zhou J, et al. A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information. Nat Commun. 2017;8(1):573.

[154] Giuliani S, Silva AC, Borba JVVB, et al. Computationally-guided drug repurposing enables the discovery of kinase targets and inhibitors as new schistosomicidal agents. PLoS Comput Biol. 2018;14(10):e1006515.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.